AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
VolitionRX Limited Common Stock
XASE · usd
SIC 2835 · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
FIGI BBG001SDZ7B2
0.17▲ 0.01 (2.96%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
EV / Revenue
EV / EBITDA
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
Trading Information
Previous Close
0.17
Day's Range
0.17 – 0.18
52-Week Range
0.13 – 3.26
Volume
506.4K
Avg Volume
2.5M
Share Statistics
Shares Outstanding
Employees
75
Exchange
XASE
Listed
2007-04-25
Share count as of August 11, 2026

VolitionRX Limited Common Stock (VNRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about VolitionRX Limited Common Stock (VNRX)
What is VolitionRX Limited Common Stock's Market Cap?
VolitionRX Limited Common Stock's Market Cap is $2.4M, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's Enterprise Value?
VolitionRX Limited Common Stock's Enterprise Value is $7.0M, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's Price / Sales?
VolitionRX Limited Common Stock's Price / Sales is 1.0×, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's EV / Revenue?
VolitionRX Limited Common Stock's EV / Revenue is 2.8×, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's EV / EBITDA?
VolitionRX Limited Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's Revenue (TTM)?
VolitionRX Limited Common Stock's Revenue (TTM) is $2.5M, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's Net Income (TTM)?
VolitionRX Limited Common Stock's Net Income (TTM) is -$25.6M, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's EBITDA?
VolitionRX Limited Common Stock's EBITDA is -$18.6M, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's Diluted EPS (TTM)?
VolitionRX Limited Common Stock's Diluted EPS (TTM) is -1.88, based on as-reported figures from SEC (XBRL) filings.
What is VolitionRX Limited Common Stock's EBITDA Margin?
VolitionRX Limited Common Stock's EBITDA Margin is -755.6%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VNRXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Services
Product
Total Revenues
YoY growth-2.0%+299.8%+133.2%+32.2%
Operating Expenses
Research and Development Expense
Selling, General and Administrative Expense
Total Operating Expenses
% of revenue1142.5%643.0%1177.9%913.2%
Operating Loss
% of revenue-1042.5%-543.0%-1077.9%-813.2%
Other Income (Expenses)
Grant income (loss)
Gain/Loss on Asset Sales (CF)—
Interest Income
Interest expense
Amortization of debt discount
Non-Operating Income (Expense)
Gain (loss) on change in fair value of warrant liability
Total Other Income (Expenses)
Net Loss
% of revenue-1835.0%-680.5%-1409.9%-862.4%
Net Loss Attributable to Non-Controlling Interest
Net Loss Attributable to VolitionRx Limited Stockholders
% of revenue-1837.7%-676.6%-1402.8%-857.4%
Net Loss Attributable to VolitionRx Limited Stockholders———
Net Loss Attributable to Common Stockholders———
Earnings Per Share (Diluted)